The Europe electroencephalography devices market size was exhibited at USD 322.75 Million in 2023 and is projected to hit around USD 847.08 Million by 2033, growing at a CAGR of 10.13% during the forecast period 2024 to 2033.
Report Coverage | Details |
Market Size in 2024 | USD 355.44 Million |
Market Size by 2033 | USD 847.08 Million |
Growth Rate From 2024 to 2033 | CAGR of 10.13% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Product, Type, Application, End-use, Country |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Country scope | Germany; U.K.; France; Italy; Spain; Denmark; Sweden; Norway |
Key Companies Profiled | Natus Medical, Inc.; Medtronic; Nihon Kohden America, Inc.; Brain Products GmbH; Neurosoft; Compumedics Ltd.; ANT Neuro; Lifelines neuro; Emotiv |
Major factors contributing to the market growth include the increasing prevalence of neurological disorders, growing R&D activities, technological advancements, and growing awareness. For instance, according to EBRAINS, the incidence of neurological conditions is steadily increasing and is expected to place a growing strain on healthcare systems as population’s age.
Collaborative research projects and partnerships among European universities, research institutes, and medical device companies are expected to lead to technological advancements and introduction of new applications for EEG in both clinical and non-clinical settings. These developments are expected to improve patient outcomes and expand the market by increasing the use of EEG in areas such as mental health, sleep research, and cognitive studies, thus driving growth in the European electroencephalography market.
In April 2024, researchers from Drexel University’s Creativity Research Lab developed an artificial intelligence (AI) technique that can effectively estimate an individual’s brain age using EEG brain scans. This technology could make early and regular screening for degenerative brain diseases more accessible. Drexel University has licensed this brain-age estimation technology to DiagnaMed Holdings, a Canadian healthcare company, for integration into a new digital health platform.
Market players focusing on the development of cost-effective Electroencephalography (EEG) devices and accessories are also expected to drive market growth. For instance, in May 2024, Viamed, a manufacturer and distributor of medical devices to the NHS, announced a new range of disposable, single-use EEG sensors. These sensors, compatible with existing Bispectral Index (BIS) monitors, offer a cost-effective alternative while also maintaining standards of care. Designed to monitor anesthesia depth using BIS derived from EEG signals, these sensors provide real-time insights into patients' consciousness and brain activity during surgeries. This is expected to reduce healthcare costs while ensuring quality care.
Neurological conditions such as epilepsy, Alzheimer's disease, Parkinson's disease, and many others are becoming increasingly common due to factors such as aging population, lifestyle changes, and improved diagnostic capabilities. For instance, the European Brain Council reports that about 7 million people in Europe currently live with Alzheimer’s disease. With the population aging rapidly, this number is expected to double to 14 million by 2033, presenting a significant public health concern.
This rise in neurological disorders necessitates advanced diagnostic tools like EEG, which are crucial for accurate diagnosis, monitoring, and treatment planning. Electroencephalography devices offer details of brain's electrical activity, helping healthcare professionals detect abnormalities, assess the severity of conditions, and monitor treatment effectiveness. As awareness of these disorders increases and healthcare systems focus on early detection and intervention, the demand for EEG devices is expected to rise.
The 32-channel EEG segment dominated the market in 2023 by capturing a share of around 27.71% and is further expected to continue its dominance over the forecast period. 32-channel EEG systems provide superior spatial resolution compared to lower-channel systems, enabling more precise monitoring of brain activity, which is essential for accurate diagnosis and treatment planning in clinical applications. Moreover, their versatility allows for use across various settings, including hospitals, clinics, and research laboratories, making them highly desirable among healthcare providers and researchers.
The multichannel EEG segment is expected to witness the fastest growth over the forecast period.Advancements in technology have made multichannel EEG systems more accessible and user-friendly, enabling their adoption across a wide range of healthcare settings. These systems are increasingly being integrated with other diagnostic modalities and technologies, such as functional magnetic resonance imaging (fMRI) and magnetoencephalography (MEG), to provide a more comprehensive assessment of brain function and connectivity.
Hospitals held the largest market share of about 68.0% in 2023.Hospitals are the primary facilities where patients visit for different medical procedures, including those that necessitate EEG monitoring. Many medical specialties and services are offered in hospitals, electroencephalography devices can be used across various departments, such as neurology, neurosurgery, intensive care units (ICUs), and emergency rooms. Moreover, hospitals have a higher patient volume compared to other healthcare settings, leading to a greater demand for EEG devices in hospitals.
The diagnostic centers segment is expected to grow at fastest rate during the forecast period. The growing incidence of neurological disorders and its growing awareness is expected to contribute to the segment growth. Diagnostic centers play an essential role in delivering specialized neurological diagnostic services to patients by offering EEG services, they help in early diagnosis and effective management of neurological conditions, which ultimately enhances patient outcomes and quality of care.
The standalone devices segment held the largest market share of 71.19% in 2023 and is expected to continue its dominance over the forecast period. Standalone EEG devices are more cost-effective than integrated systems, expanding their accessibility to a wider range of healthcare settings, including smaller clinics and outpatient facilities. Furthermore, standalone Electroencephalography (EEG) devices commonly feature user-friendly interfaces and controls, allowing healthcare professionals to operate them with ease. Thus, the aforementioned benefits are expected to contribute to the segment growth.
The portable device segment is expected to grow at the fastest CAGR over the forecast period. The rising need for remote patient monitoring and home-based healthcare solutions is increasing the adoption of portable Electroencephalography
(EEG) devices. These devices enable convenient and non-invasive monitoring of brain activity beyond traditional clinical settings, allowing patients to undergo EEG tests in the comfort of their homes. Additionally, technological advancements have resulted in the development of compact, lightweight, and battery-powered portable EEG devices, enhancing their portability and user-friendliness.
The disease diagnosis segment held the largest market share of about 32.0% in Europe's market. electroencephalography devices offer valuable insights into brain function and activity by detecting and recording the electrical signals generated by neurons in the brain. This enables healthcare professionals to evaluate a wide range of neurological conditions. EEG is particularly effective in diagnosing disorders like epilepsy, sleep disorders, and specific brain injuries or tumors. Through the analysis of brain wave patterns and frequencies, EEG helps in identifying abnormalities that may indicate these conditions.
The trauma & surgery segment is expected to grow at the fastest CAGR over the forecast period, this is primarily due to the rising incidence of injuries and accidents, which consequently leads to an increase in surgical interventions. Moreover, as the number of traumatic incidents rises, the need for surgical procedures to address resulting injuries also increases. Thus, Electroencephalography devices are essential in helping medical professionals monitor brain function during surgeries and trauma management.
The electroencephalography devices market in UK held a significant share in 2023. The UK has a well-defined healthcare system that consists of advanced medical technologies, including EEG devices. These devices are extensively used across hospitals, clinics, and research institutions for diagnosing and tracking a range of neurological conditions like epilepsy, sleep disorders, and brain injuries. Furthermore, the rising geriatric population and growing awareness regarding neurological disorders are increasing the need for electroencephalography devices in the country.
Germany Electroencephalography Devices Market Trends
Germany electroencephalography devices market is expected to grow owing to the growing prevalence of neurological disorders in the country and different strategic initiatives undertaken by market players in the country. For instance, in September 2022 , Brainlab announced the acquisition of Dr. Langer Medical GmbH. Headquartered in Waldkirch, Germany, this strategic acquisition signifies Brainlab's commitment to expanding its portfolio of innovative medical technologies, particularly in the realm of intraoperative neurosurgery.
France Electroencephalography Devices Market Trends
The electroencephalography devices market in France is expected to grow owing to technological advancements and the growing incidence of neurological disorders in the country. For instance, according to statistics from NCBI, stroke ranks as the second leading cause of mortality in France, with approximately 30,000 fatalities annually and around 110,000 hospitalizations each year.
This report forecasts revenue growth at country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the Europe electroencephalography devices market
Product
Type
Application
End Use Channel
Country
Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Product
1.2.2. Type
1.2.3. Application
1.2.4. End Use
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.4.5.1. Data for primary interviews in North America
1.4.5.2. Data for primary interviews in Europe
1.4.5.3. Data for primary interviews in Asia Pacific
1.4.5.4. Data for primary interviews in Latin America
1.4.5.5. Data for Primary interviews in MEA
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product outlook
2.2.2. Type outlook
2.2.3. Application outlook
2.2.4. End-use outlook
2.2.5. Regional outlook
2.3. Competitive Insights
Chapter 3. Europe Electroencephalography Devices Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. Increasing prevalence of neurological diseases
3.2.1.2. Growing R&D activities,
3.2.1.3. Technological advancements
3.2.2. Market restraint analysis
3.2.2.1. Lack of skilled professionals
3.3. Europe Electroencephalography Devices Market Analysis Tools
3.3.1. Industry Analysis - Porter’s Five Forces
3.3.1.1. Supplier power
3.3.1.2. Buyer power
3.3.1.3. Substitution threat
3.3.1.4. Threat of new entrant
3.3.1.5. Competitive rivalry
3.3.2. PESTEL Analysis
3.3.2.1. Political landscape
3.3.2.2. Technological landscape
3.3.2.3. Economic landscape
Chapter 4. Europe Electroencephalography Devices Market: Product Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Global Europe EEG Devices Product Market Movement Analysis
4.3. Global Europe Electroencephalography Devices Market Size & Trend Analysis, by Product, 2021 to 2033
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.5. 8-channel EEG
4.5.1. 8-channel EEG market estimates and forecasts 2021 to 2033
4.6. 21-channel EEG
4.6.1. 21-channel EEG market estimates and forecasts 2021 to 2033
4.7. 25-channel EEG
4.7.1. 25-channel EEG market estimates and forecasts 2021 to 2033
4.8. 32-channel EEG
4.8.1. 32-channel EEG market estimates and forecasts 2021 to 2033
4.9. 40-channel EEG
4.9.1. 40-channel EEG market estimates and forecasts 2021 to 2033
4.10. Multichannel EEG
4.10.1. Multichannel EEG market estimates and forecasts 2021 to 2033
Chapter 5. Europe Electroencephalography Devices Market: Type Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Europe EEG Devices Type Market Movement Analysis
5.3. Europe Electroencephalography Devices Market Size & Trend Analysis, by Type, 2021 to 2033
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.5. Standalone Devices
5.5.1. Standalone devices market estimates and forecasts 2021 to 2033
5.6. Portable Devices
5.6.1. Portable devices market estimates and forecasts 2021 to 2033
5.7. Wearable Devices
5.7.1. Wearable devices market estimates and forecasts 2021 to 2033
Chapter 6. Europe Electroencephalography Devices Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Europe EEG Devices Application Market Movement Analysis
6.3. Europe Electroencephalography Devices Market Size & Trend Analysis, by Application, 2021 to 2033
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.5. Trauma & Surgery
6.5.1. Trauma & surgery market estimates and forecasts 2021 to 2033
6.6. Disease Diagnosis
6.6.1. Disease diagnosis market estimates and forecasts 2021 to 2033
6.7. Anesthesia Monitoring
6.7.1. Anesthesia monitoring market estimates and forecasts 2021 to 2033
6.8. Sleep Monitoring
6.8.1. Sleep monitoring market estimates and forecasts 2021 to 2033
6.9. Others
6.9.1. Others market estimates and forecasts 2021 to 2033
Chapter 7. Europe Electroencephalography Devices Market: End Use Estimates & Trend Analysis
7.1. Segment Dashboard
7.2. Europe EEG Devices End Use Market Movement Analysis
7.3. Europe Electroencephalography Devices Market Size & Trend Analysis, by End Use, 2021 to 2033
7.4. Hospitals
7.4.1. Hospitals market estimates and forecasts 2021 to 2033
7.5. Diagnostic Centers
7.5.1. Diagnostic centers market estimates and forecasts 2021 to 2033
7.6. Others
7.6.1. Others market estimates and forecasts 2021 to 2033
Chapter 8. Europe Electroencephalography Devices Market: Country Estimates & Trend Analysis By Product, Type, Application, End Use
8.1. Country Market Share Analysis, 2024 & 2033
8.2. Country Market Dashboard
8.3. Regional Market Snapshot
8.4. Market Size, & Forecasts Trend Analysis, 2021 to 2033
8.5. Europe
8.5.1. Regulatory framework/ reimbursement structure
8.5.2. UK
8.5.2.1. Key country dynamics
8.5.2.2. Competitive scenario
8.5.2.3. Regulatory framework/ reimbursement structure
8.5.2.4. UK market estimates and forecasts 2021 to 2033
8.5.3. Germany
8.5.3.1. Key country dynamics
8.5.3.2. Competitive scenario
8.5.3.3. Regulatory framework/ reimbursement structure
8.5.3.4. Germany market estimates and forecasts 2021 to 2033
8.5.4. France
8.5.4.1. Key country dynamics
8.5.4.2. Competitive scenario
8.5.4.3. Regulatory framework/ reimbursement structure
8.5.4.4. France market estimates and forecasts 2021 to 2033
8.5.5. Italy
8.5.5.1. Key country dynamics
8.5.5.2. Competitive scenario
8.5.5.3. Regulatory framework/ reimbursement structure
8.5.5.4. Italy market estimates and forecasts 2021 to 2033
8.5.6. Spain
8.5.6.1. Key country dynamics
8.5.6.2. Competitive scenario
8.5.6.3. Regulatory framework/ reimbursement structure
8.5.6.4. Spain market estimates and forecasts 2021 to 2033
8.5.7. Norway
8.5.7.1. Key country dynamics
8.5.7.2. Competitive scenario
8.5.7.3. Regulatory framework/ reimbursement structure
8.5.7.4. Norway market estimates and forecasts 2021 to 2033
8.5.8. Sweden
8.5.8.1. Key country dynamics
8.5.8.2. Competitive scenario
8.5.8.3. Regulatory framework/ reimbursement structure
8.5.8.4. Sweden market estimates and forecasts 2021 to 2033
8.5.9. Denmark
8.5.9.1. Key country dynamics
8.5.9.2. Competitive scenario
8.5.9.3. Regulatory framework/ reimbursement structure
8.5.9.4. Denmark market estimates and forecasts 2021 to 2033
Chapter 9. Competitive Landscape
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Key company market share analysis, 2024
9.4. Company Position Analysis
9.5. Company Categorization (Emerging Players, Innovators and Leaders
9.6. Company Profiles
9.6.1. Natus Medical, Inc.
9.6.1.1. Company overview
9.6.1.2. Financial performance
9.6.1.3. Product benchmarking
9.6.1.4. Strategic initiatives
9.6.2. Medtronic
9.6.2.1. Company overview
9.6.2.2. Financial performance
9.6.2.3. Product benchmarking
9.6.2.4. Strategic initiatives
9.6.3. Nihon Kohden America, Inc.
9.6.3.1. Company overview
9.6.3.2. Financial performance
9.6.3.3. Product benchmarking
9.6.3.4. Strategic initiatives
9.6.4. Brain Products GmbH
9.6.4.1. Company overview
9.6.4.2. Financial performance
9.6.4.3. Product benchmarking
9.6.4.4. Strategic initiatives
9.6.5. Neurosoft
9.6.5.1. Company overview
9.6.5.2. Financial performance
9.6.5.3. Product benchmarking
9.6.5.4. Strategic initiatives
9.6.6. Compumedics Ltd.
9.6.6.1. Company overview
9.6.6.2. Financial performance
9.6.6.3. Product benchmarking
9.6.6.4. Strategic initiatives
9.6.7. ANT Neuro
9.6.7.1. Company overview
9.6.7.2. Financial performance
9.6.7.3. Product benchmarking
9.6.7.4. Strategic initiatives
9.6.8. Lifelines neuro
9.6.8.1. Company overview
9.6.8.2. Financial performance
9.6.8.3. Product benchmarking
9.6.8.4. Strategic initiatives
9.6.9. Emotiv
9.6.9.1. Company overview
9.6.9.2. Financial performance
9.6.9.3. Product benchmarking
9.6.9.4. Strategic initiatives